1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

SUPN
Supernus Pharmaceuticals, Inc.US flagNASDAQ Global Market
43.97
USD
-0.06
- -
2.55BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.38
2.19
3.11
4.35
5.95
7.86
7.49
9.89
10.92
12.43
11.14
12.01
12.74
14.47
Basic EPS, GAAP
-2.9
-0.26
0.29
1.84
1.13
2.13
2.16
2.41
1.01
1.13
0.02
1.34
-0.68
-1.91
Free Cash Flow per Basic Share
-1.89
-0.59
0.68
1.32
2.22
2.46
2.7
2.56
2.36
2.17
2.03
3.11
0.81
0.33
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.84
0.95
1.8
3.84
5.21
8.66
11.33
14.09
15.32
16.33
16.84
18.58
18.48
17.73
Tangible Book Value per Share
0.81
0.94
1.78
3.11
4.51
8.06
10.86
5.72
-1.62
1.23
3.74
7.12
6.39
7.6
Basic Weighted Avg Shares
32
42
47
49
51
52
52
53
53
54
55
55
56
57
Sales/Revenue/Turnover
12
93
147
215
302
409
393
520
580
667
608
662
719
830
Operating Margin (%)
-515.18
-5.69
14.13
25.22
32.93
35.33
37.83
33.74
13.71
6.84
2.21
11.42
-5.13
-6.67
Depreciation Expense
1
1
1
2
8
7
7
18
33
86
85
80
92
102
Net Income, GAAP
-92
-11
14
91
57
111
113
127
53
61
1
74
-39
-110
Effective Tax Rate (%)
- -
- -
4.56
- -
43.07
20.82
23.35
24.72
26.99
0.05
52.47
24.53
- -
- -
Profit Margin (%)
-767.73
-11.79
9.46
42.43
18.95
27.14
28.79
24.39
9.21
9.1
0.22
11.16
-5.36
-13.23
Working Capital
71
81
49
71
105
332
312
385
286
46
203
394
306
376
LT Debt
34
26
7
4
- -
329
376
411
421
36
33
27
30
29
Total Equity
33
41
88
192
267
453
595
745
816
886
922
1,036
1,062
1,031
Return on Invested Capital (%)
- -
- -
24.56
- -
24.09
21.62
13.03
12.51
4.88
3.58
0.56
5.67
- -
- -
Return on Capital (%)
- -
- -
22.83
- -
25.11
23.87
14.86
13.58
5.87
5.27
0.21
7.27
- -
- -
Return on Common Equity (%)
-202.72
-29.46
21.67
65.21
24.95
30.81
21.57
18.94
6.85
7.13
0.15
7.55
-3.68
-10.49

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11
11
11
LT Borrowings
- -
- -
- -
LT Finance Leases
30
30
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
57
58
58
Market Capitalization
2,856
3,000
2,705

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
644
732
723
Cash, Cash Equivalents & STI
309
384
372
Accounts Receivable, Net
188
182
212
Inventories
82
87
84
Total Current Liabilities
338
374
347
Payables & Accruals
229
256
272
ST Debt
11
11
11
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
32.03%
7.41%
2.51%
Free Cash Flow
15.59%
-7.47%
-73.14%
Net Income, GAAP
584.35%
1,043.71%
-152.19%
Sales/Revenue/Turnover
18.53%
7.02%
8.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
144
168
176
174
662
2025
150
165
192
212
719
2026
208
219
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.36
0.7
0.28
1.34
2025
-0.21
0.4
-0.8
-0.07
-0.68
2026
-0.04
-1.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jack A. Khattar
Full Time Employees
778
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
9715 Key West Avenue Rockville MD United States of America 20850
IPO Date
May 1, 2012
CIK
0001356576
Website
supernus.com
Similar Companies
Porton Pharma Solutions Ltd. (300363.SZ)
Aurora Cannabis Inc. (ACB)
OMID Holdings, Inc. (OMID)
Zhejiang Shengda Bio-Pharm Co., Ltd. (603079.SS)
Invion Limited (IVIXF)
The Green Organic Dutchman Holdings Ltd. (TGODD)
Business
Supernus Pharmaceuticals, Inc. (SUPN) develops and commercializes products for the treatment of central nervous system (CNS) disorders, epilepsy, and other neurological conditions. The company offers a portfolio of branded products including Trokendi XR (extended-release topiramate) for epilepsy and migraine prevention; Oxtellar XR (extended-release oxcarbazepine) for partial seizure treatment; Qudexy XR (extended-release topiramate) for epilepsy and migraine prophylaxis; and SPN-817, an investigational product in clinical development for treatment-resistant epilepsy. Additional pipeline candidates include SPN-830 (apomorphine infusion device for Parkinson's disease motor fluctuations) and SPN-820 (viloxazine extended-release for major depressive disorder), with research focused on novel formulations and delivery systems for CNS therapeutics. Supernus operates primarily in the United States, with headquarters in Rockville, Maryland, where it was founded in 2005. In recent developments, Supernus strengthened its epilepsy portfolio through the 2024 FDA approval and launch of a generic equivalent to Epidiolex (cannabidiol oral solution), expanding access to treatments for rare epilepsy syndromes such as Lennox-Gastaut syndrome and Dravet syndrome. The company also advanced its pipeline with positive topline results from the Phase 3 trial of SPN-817 in mid-2025, supporting a New Drug Application submission planned for late 2025, and initiated a strategic collaboration with a leading device manufacturer for the SPN-830 infusion pump commercialization. No major acquisitions, funding rounds, or reorganizations have been reported in the last two years, allowing focus on organic growth and regulatory milestones in the competitive CNS pharmaceuticals segment targeting neurologists, epileptologists, and pediatric specialists.

Company News

Company News APIChatGPT

  • globenewswire.com

    Supernus Pharmaceuticals to Participate in September Investor Conferences

  • globenewswire.com

    Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

  • gurufocus.com

    SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

  • businesswire.com

    SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

  • defenseworld.net

    BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

  • zacks.com

    Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

  • defenseworld.net

    Critical Survey: Vectura Group (OTCMKTS:VEGPF) versus Supernus Pharmaceuticals (NASDAQ:SUPN)

  • defenseworld.net

    Allworth Financial LP Invests $2.36 Million in Supernus Pharmaceuticals, Inc. $SUPN

  • zacks.com

    Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

  • defenseworld.net

    Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE

  • defenseworld.net

    Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.

  • defenseworld.net

    California State Teachers Retirement System Grows Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

  • prnewswire.com

    Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders?

  • zacks.com

    SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

  • gurufocus.com

    Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

  • businesswire.com

    Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

  • zacks.com

    New Strong Buy Stocks for August 7th

  • zacks.com

    Best Value Stocks to Buy for August 7th

  • zacks.com

    INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

  • fool.com

    Why Supernus Pharmaceuticals Stock Topped the Market Today